Envista Holdings Corporation

19.98-0.08 (-0.4%)

Oct 29, 4:00:02 PM EDT · NYSE · NVST · USD

Upcoming Earnings

Report date

Oct 30, 2025 (today)

EPS

0.27 (0.25 ~ 0.30)

Revenue

651.06M (646.00M ~ 659.90M)

Key Stats

Market Cap

3.32B

P/E (TTM)

62.44

Basic EPS (TTM)

0.32

Dividend Yield

Recent Filings

8-K

10/29/25Oct 29, 2025

8-K

10/29/25Oct 29, 2025

8-K

Board director resigns amicably

9/17/25Sep 17, 2025

Envista Holdings Corporation announced that board director Barbara B. Hulit resigned effective September 26, 2025, to pursue another opportunity. Her departure stems from no disagreements over operations, policies, or practices. The board loses an experienced voice. No successor named yet.

10-Q

Q2 FY2025 results

7/31/25Jul 31, 2025

Envista's Q2 sales climbed 7.7% year-over-year to $682.1M, fueled by 4.1% volume gains and 1.5% pricing lift, while gross margin expanded 2.6 points to 54.2% on higher throughput and no repeat of last year's impairments. Operating profit swung to $46.3M from a $1,153.3M loss, with diluted EPS at $0.16 versus $(6.69); YTD figures show 3.4% sales growth to $1,299.0M and EPS of $0.26, reconciling cleanly to 171.7M diluted shares. Specialty Products & Technologies drove momentum with 7.2% sales rise, while Equipment & Consumables added 8.7%, both benefiting from North America and Europe but softening in China. Cash swelled to $1,110.6M, operating cash flow hit $89.0M YTD, and free cash flow stood at $70.8M after $18.2M capex; total debt eased to $1,445.1M post-2025 convertible repayment, with revolver availability intact under covenants. Repurchased $100.3M in shares YTD. Yet regulatory pricing pressures in emerging markets linger.

8-K

Envista Q2 sales hit $682M

7/31/25Jul 31, 2025

Envista Holdings reported Q2 2025 sales of $682 million, up 7.7% year-over-year, with core sales growth accelerating to 5.6% as all major businesses and geographies expanded. Adjusted EBITDA surged 34% to $84 million, boosting margins by 240 basis points to 12.4%, while net income flipped to $26 million from a $1.152 billion loss. Growth fueled investments in operations and people. Shares repurchased: 4.8 million for $82 million. Full-year guidance raised to 3-4% core sales growth and $1.05-$1.15 adjusted EPS. Momentum builds, yet cash flow dipped.

About

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

CEO

Mr. Paul A. Keel

IPO

9/18/2019

Website

https://envistaco.com

Employees

12,300

Sector

Healthcare

Industry

Medical Instruments & Supplies